In Situ Phase-Transited Asymmetric Membrane Capsules: A Means for Achieving Delayed and Osmotic Release for pH Solubility-Dependant Drugs

References

1. 1.↵
   1. Santus G.,
   2. Baker R. W.

   Osmotic drug delivery: a review of the patent literature. J. Controlled Release 1995, 35 (1), 1–21.

   OpenUrl
2. 2.↵
   1. Theeuwes F.

   Elementary osmotic pump. J. Pharm. Sci. 1975, 64 (12), 1987–1991.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Theeuwes F.,
   2. Saunders R. J.,
   3. Mefford W. S.

   Process for Forming Outlet Passageways in Pills Using a Laser. US Patent 4,088,864, 1978.
4. 4.↵
   1. Herbig S. M.,
   2. Cardinal J. R.,
   3. Korsmeyer R. W.,
   4. Smith K. L.

   Asymmetric membrane tablet coatings for osmotic drug delivery. J. Controlled Release 1995, 35 (2–3), 127–136.

   OpenUrl
5. 5.↵
   1. Philip A. K.,
   2. Pathak K.

   Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility. AAPS PharmSciTech 2006, 7 (3), 21–25.

   OpenUrl
6. 6.↵
   1. Philip A.,
   2. Pathak K.

   In-situ formed asymmetric membrane capsule for osmotic release of poorly water-soluble drug. PDA J. Pharm. Sci. Technol. 2007, 61 (1), 24–36.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Philip A. K.,
   2. Pathak K.

   Wet process-induced phase-transited drug delivery system: a means for achieving osmotic, controlled and level A IVIVC for poorly water-soluble drug. Drug Dev. Ind. Pharm. 2008, 34 (7), 735–743.

   OpenUrlPubMed
8. 8.↵
   1. Philip A. K.,
   2. Pathak K.,
   3. Shakya P.

   Asymmetric membrane in membrane capsules: a means for achieving delayed and osmotic flow of cefadroxil. Eur. J. Pharm. Biopharm. 2008, 69 (2), 658–666.

   OpenUrlPubMed
9. 9.↵
   1. Gupta S. K.,
   2. Atkinson L.,
   3. Theeuwes F.,
   4. Wong P.,
   5. Longstreth J.

   Pharmacokinetics of verapamil from an osmotic system with delayed onset. Eur. J. Pharm. Biopharm. 1996, 42 (1), 74–81.

   OpenUrl
10. 10.↵
    1. Grundy J. S.,
    2. Foster R. T.

    The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties. Clin. Pharmacokinet. 1996, 30 (1), 28–51.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. La Rosa F.,
    2. Ripa S.,
    3. Prenna M.,
    4. Ghezzi A.,
    5. Pfeffer M.

    Pharmacokinetics of cefadroxil after oral administration in humans. Antimicrob. Agents Chemother. 1982, 21 (2), 320–322.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Buck R. E.,
    2. Price K. E.

    Cefadroxil, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 1977, 11 (2), 324–330.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Schnurch A. B.,
    2. Guggi D.,
    3. Pinter Y.

    Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system. J. Controlled Release 2004, 94 (1), 177–186.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Bhagwati S. T.,
    2. Hiremath S. M.,
    3. Sreeniwas S. A.

    Formulation and evaluation of cefadroxil dispersible tablets. Pharm. Rev. 2006, 4, 136–139.

    OpenUrl
15. 15.↵
    1. Sweetman S. C.

    Martindale—The Complete Drug Reference, 5th ed; Pharmaceutical Press: London, 2002; pp 161–162.
16. 16.↵
    1. McClelland G. A.,
    2. Sutton S. C.,
    3. Engle K.,
    4. Zentner G. M.

    The solubility-modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride. Pharm. Res. 1991, 8 (1), 88–92.

    OpenUrlPubMed
17. 17.↵
    1. Zentner G. M.,
    2. McClelland G. A.,
    3. Sutton S. C.

    Controlled porosity solubility- and resin-modulated osmotic drug delivery systems for release of diltiazem hydrochloride. J. Controlled Release 1991, 16 (1–2), 237–244.

    OpenUrl
18. 18.↵
    1. Martin A.

    Physical pharmacy, 3rd ed; B. I. Waverly Pvt.: New Delhi, India; 1999; p 72.
19. 19.↵
    United States Pharmacopoeia, 4th ed; United State Pharmacopoeial Convention: Rockville, MD, 2004; p 2308.
20. 20.↵
    1. Najib N.,
    2. Suleiman M.

    The kinetics of drug release from ethylcellulose solid dispersions. Drug Dev. Ind. Pharm. 1985, 11, 2169–2181.

    OpenUrlCrossRefWeb of Science
21. 21.↵
    1. Desai S. J.,
    2. Singh P.,
    3. Simonelli A. P.,
    4. Higuchi W. I.

    Investigation of factors influencing release of solid drug dispersed in wax matrices. III. Quantitative studies involving the polyethylene plastic matrix. J. Pharm. Sci. 1966, 55 (11), 1230–1234.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Higuchi T.

    Mechanism of sustained action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci. 1963, 52 (12), 1145–1149.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    1. Hixson A. W.,
    2. Crowell J. H.

    Dependence of reaction velocity upon surface and agitation. I. Theoretical consideration. Ind. Eng. Chem. 1931, 23 (8), 923–931.

    OpenUrlCrossRef
24. 24.↵
    1. Korsmeyer R. W.,
    2. Gurny R.,
    3. Doelker E. M.,
    4. Buri P.,
    5. Peppas N. A.

    Mechanism of solute release from porous hydrophilic polymers. Int. J. Pharm. 1983, 15 (1), 25–35.

    OpenUrlCrossRefWeb of Science
25. 25.↵
    1. Jensen J. L.,
    2. Appel L. E.,
    3. Clair J. H.,
    4. Zentner G. M.

    Variables that affect the mechanism of drug release from osmotic pumps coated with acrylate/methacrylate copolymer latexes. J. Pharm. Sci. 1995, 84 (5), 530–533.

    OpenUrlPubMed
26. 26.↵
    1. Kamba M.,
    2. Seta Y.,
    3. Kusai A.,
    4. Nishimura K.

    Evaluation of the mechanical destructive force in the stomach of dog. Int. J. Pharm. 2000, 208 (1–2), 61–70.

    OpenUrlCrossRefPubMedWeb of Science
27. 27.↵
    1. Kamba M.,
    2. Seta Y.,
    3. Kusai A.,
    4. Ikeda M.,
    5. Nishimura K.

    A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract. Int. J. Pharm. 2001, 228 (1–2), 209–217.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Mei X.,
    2. Etzler F. M.,
    3. Wang Z.

    Use of texture analysis to study hydrophilic solvent effects on the mechanical properties of hard gelatin capsules. Int. J. Pharm. 2006, 324 (2), 128–135.

    OpenUrlPubMed